Literature DB >> 177447

Impaired LH release following exogenous estrogen administration in patients with amenorrhea-galactorrhea syndrome.

T Aono, A Miyake, T Shioji, T Kinugasa, T Onishi.   

Abstract

Serum gonadotropin levels were determined in 10 patients with the amenorrhea-galactorrhea syndrome before and following acute iv administration of synthetic LH-releasing hormone (LHRH) or conjugated estrogens, in order to clarify the hypothalamic derangements in the gonadotropin secretion in patients with hyperprolactinemia. The basal prolactin (PRL) levels were elevated in all the patients, and blunted responses to 500 mug of iv synthetic thyrotropin-releasing hormone (TRH) injection were found in 9 out of the 10 patients. The basal levels of LH and FSH were subnormal in 2 and 3 patients, respectively, while those in the remaining patients were normal or slightly elevated. Normal or excessive responses of gonadotropins to 100 mug of iv LHRH were observed in most patients, 9 for LH and 10 for FSH out of 10 patients. In 10 normal cyclic women at the mid-follicular phase (D7-9) and 10 hypothalamic amenorrhea patients without galactorrhea, LH release was found 48 to 72 h after the iv injection of 20 mg conjugated estrogens (Premarin). This LH release following Premarin injection was completely abolished in the patients with amenorrhea-galactorrhea. These data seem to indicate that in patients with hyperprolactinemia, tonic secretion of gonadotropin is maintained fairly well, while of the positive feedback effect of Premarin on the release of LH is impaired. It is suggested that impaired LH release may be partly responsible for anovulation and amenorrhea in patients with hyperprolactinemia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177447     DOI: 10.1210/jcem-42-4-696

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Hypothalamic-pituitary-ovarian function in hyperprolactinemic women.

Authors:  P Travaglini; B Ambrosi; P Beck-Peccoz; R Elli; M Rondena; R Bara; G Weber
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

2.  [Clinical endocrine investigations in patients with pituitary adenoma (author's transl)].

Authors:  D Mühlenstedt; J Hanker; H P Schneider
Journal:  Arch Gynakol       Date:  1978-07-19

3.  Serum LH increase after estradiol and progesterone administration in hyperprolactinemic women.

Authors:  P Travaglini; R Elli; B Ambrosi; M Ballabio; P Moriondo; G Faglia
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

4.  [Hyperprolactinemia and sterility].

Authors:  H K Rjosk; R Fahlbusch; K von Werder
Journal:  Arch Gynecol       Date:  1979-07-20

Review 5.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

6.  Mass screening for hyperprolactinemia and prolactinoma in men.

Authors:  A Miyake; M Ikegami; C F Chen; N Arita; T Aono; O Tanizawa; T Yoshikawa
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

Review 7.  [Human prolactin (author's transl)].

Authors:  K von Werder; H K Rjosk
Journal:  Klin Wochenschr       Date:  1979-01-01

8.  Hyperprolactinemia and estrogen-induced rhythms in LH and prolactin release in the ovariectomized rat.

Authors:  L Carr; D Rotten; H Scherrer; C Kordon
Journal:  Experientia       Date:  1985-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.